Differing effects of low-dose estrogen-progestin therapy and pravastatin in postmenopausal hypercholesterolemic women

Climacteric

Volumn 5, Issue 4, 2002, Pages 341-350

  Davis, S R ^a   Goldstat, R ^a   Newman, A ^a   Berry, K ^b   Burger, H G ^a   Meredith, I ^a   Koch, K ^c  

^a Jean Hailes Foundation for Women's Health   (Australia)

^b MONASH MEDICAL CENTRE   (Australia)

^c NOVO NORDISK A S   (Denmark)

Author keywords

Estrogen; Hormone replacement therapy; Hypercholesterolemia

Indexed keywords

CHOLESTEROL; ESTRADIOL PLUS NORETHISTERONE ACETATE; FIBRINOGEN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PRAVASTATIN; TRIACYLGLYCEROL;

ADULT; AGED; ARTERY BLOOD FLOW; ARTERY DIAMETER; ARTERY DILATATION; ARTICLE; BLOOD VESSEL REACTIVITY; BRACHIAL ARTERY; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DIET THERAPY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; ENDOTHELIUM INJURY; FEMALE; FIBRINOGEN BLOOD LEVEL; GASTROINTESTINAL SYMPTOM; HEART INFARCTION; HEART PROTECTION; HIGH RISK PATIENT; HORMONE SUBSTITUTION; HUMAN; HYPERCHOLESTEROLEMIA; LIPOPROTEIN BLOOD LEVEL; LONG TERM CARE; MAJOR CLINICAL STUDY; MASTALGIA; POSTMENOPAUSE; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; TREATMENT OUTCOME; WEIGHT REDUCTION;

EID: 0036970664     PISSN: 13697137     EISSN: None     Source Type: Journal    
DOI: 10.1080/cmt.5.4.341.350     Document Type: Article

References (35)

1. Gerhard M, Ganz P. How do we explain the clinical benefits of estrogen? Circulation 1995;92:5-8
2. Grodstein F, Stampfer MJ, Colditz GA, et al. Postmenopausal estrogen and progestin use and the risk of cardiovascular disaease. N Engl J Med 1996;335:453-61
3. Grodstein F, Manson JE, Colditz GA, Willett WC, Speizer FE, Stampfer MJ. A prospective, observational study of postmenopausal hormone therapy and primary prevention of cardiovascular disease. Ann Intern Med 2000;133:933-41
4. Mattsson L-A. Clinical experience with transdermal continuous combined HRT. Gynecol Endocrinol 1998;12:25-8
5. Genant H, Lucas J, Weiss S, et al. Low-dose esterified estrogen therapy, effects on bone, plasma estradiol concentrations, endometrium, and lipids levels. Arch Intern Med 1997;157:2609-15
6. Sacks FM, Pfeiffer MA, Lemuel AM. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996;335:1001-9
7. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383-9
8. The Lipid Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998;339:1349-57
9. Darling GM, Johns JA, McCloud PI, Davis SR. Estrogen and progestin compared with simvastatin for hypercholesterolemia in postmenopausal women. N Engl J Med 1997;337:595-601
10. Lieberman EH, Gerhard MD, Uehata A, et al. Estrogen improves endothelium-dependent, flow mediated vasodilation in postmenopausal women. Ann Intern Med 1994;121:936-41
11. Herrington DM, Braden GA, Williams JK, Morgan TM. Endothelial-dependent coronary vasomotor repsonsiveness in postmenopausal women with and without estrogen replacement therapy. Am J Cardiol 1994;73:951-2
12. Anderson TJ, Uehata A, Gerhard MD, et al. Close correlation of endothelial function in the human coronary and peripheral circulation. J Am Coll Cardiol 1995;26:1235-41
13. Kannel WB. Metabolic risk factors for coronary heart disease in women: perspective from the Framingham Study. Am Heart J 1987;114:413-19
14. Lindhal B, Toss H, Siegbahn A, Venge P, Wallentin L. Markers of myocardial damage and inflammation in relation to long term mortality in unstable coronary artery disease. N Engl J Med 2000;343:1139-47
15. Koh KK, Mincemoyer R, Bui MN, et al. Effects of hormone-replacement therapy on fibrinolysis in postmenopausal women. N Engl J Med 1997;336:683-90
16. Australian Health Insurance Commission. Pharmaceutical Benefits Schedule Item Statistics. Canberra: Australian Federal Government, 13 March 2001
17. Friedewald WT, Levy RI, Frederickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972;18:499-502
18. Sirridge MS, Shannon R. Laboratory Evaluation of Haemostasis and Thrombosis. Philadelphia: Lea and Febiger, 1983:163
19. New G, Timmins KL, Dully SJ, et al. Long-term estrogen therapy improves vascular function in male to female transsexuals. J Am Coll Cardiol 1997;29:1437-44
20. Hawthorn G, Richardson J, Osborne R, McNeil H. Australian Quality of Life Questionnaire. Centre for Health Programs and Evaluations, 1997. http://buseco.monash.edu.au/pubs/wp66
21. The EuroQoL Group. EuroQol - a new facility for the measurement of health-related quality of life. Health Policy 1990;16:199-208
22. Hunter M. The Women's Health Questionnaire: a measure of mid-aged women's perceptions of their emotional and physical health. Psychol Health 1992;7:45-54
23. Division of Metabolic and Endocrine Drug Products, Food and Drug Administration. Guidelines for the Clinical Evaluation of Lipid-Lowering Agents in Adults and Children. Washington, DC: FDA, 1990
24. The Writing Group for the Postmenopausal Estrogen/Progestin Interventions Trial. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. J Am Med Assoc 1995;273:199-208
25. Hulley S, Grady D, Bush T, et al. Heart and Estrogen/progestin Replacement Study Research Group. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. J Am Med Assoc 1996;280:605-12
26. Koh KK, Cardillo C, Bui MN, et al. Vascular effects of estrogen and cholesterol-lowering therapies in hypercholesterolemic postmenopausal women. Circulation 1999;99:354-60
27. Davidson MH, Testolin LM, Maki KC, von Duvillard S, Drennan KB. A comparison of estogen replacement, pravastatin, and combined treatment for the management of hypercholesterolemia in postmenopausal women. Arch Intern Med 1997;157:1186-92
28. Denke MA. Effects of continuous combined hormone replacement therapy on lipid levels in hypercholestolemic postmenopausal women. Am J Med 1995;99:29-35
29. Granfone A, Campos H, McNamara JR. Effects of oestrogen replacement on plasma lipoproteins and apolipoproteins in postmenopausal dyslipidemic women. Metabolism 1992;41:1193-8
30. Shlipak M, Simon J, Vittinghoff E, et al. Estrogen and progestin, lipoprotein(a) and the risk of recurrent coronary heart disease after menopause. J Am Med Assoc 2000;283:1845-52
31. Farish E, Fletcher CD, Dagen MM. Lipoprotein and apolipoprotein levels in postmenopausal women on continuous oestrogen/progestogen therapy. Br J Obstet Gynaecol 1989;96:358-64
32. Celemajer DS, Sorensen K, Gooch V, et al. Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis. Lancet 1992;340:1111-15
33. Dupuis J, Tardif JC, Cernacek P, Theroux P. Cholesterol reduction rapidly improves endothelial function after acute coronary syndromes. The RECIFE (reduction of cholesterol in ischemia and function on the endothelium trial). Circulation 1999;99:3227-33
34. Cohen JD, Drury JH, Ostdiek J, et al. Benefits of lipid lowering on vascular reactivity in patients with coronary artery disease and average cholesterol levels: a mechanism for reducing clinical events? Am Heart J 2000;139:734-8
35. Jick H, Derby LE, Myers MW, Vasilakis C, Newton KM. Risk of hospital admission for idiopathic venous thromboembolism among users of postmenopausal oestrogens. Lancet 1996;348:981-3